 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- | CERE-110 / Biogen
Preclinical, Journal: AAV2/9-mediated gene transfer into murine lacrimal gland leads to a long-term targeted tear film modification. (Pubmed Central) - Sep 30, 2022
Remarkably, AAV2/9 induces an important and long-lasting secretion of this growth factor in the tear film. Altogether, our findings provide a new clinically applicable approach to tackle corneal blindness.
- | CERE-110 / Biogen
Journal: Nerve growth factor protects salivary glands from irradiation-induced damage. (Pubmed Central) - Feb 3, 2021
Altogether, our findings provide a new clinically applicable approach to tackle corneal blindness. The current study findings indicated that the modulation of the NGF pathway might prevent IR-induced salivary hypo-function.
- CERE-110 / Biogen
[VIRTUAL] 3D neural circuit visualization by neural tracing and tissue clearing for dementia study () - Aug 2, 2020 - Abstract #AAIC2020AAIC_381;
Taken together, nigrostriatal pathway, connecting substantia nigra and striatum, can be traced by using neural tracers together with tissue clearing. With this protocol, the neural circuits related to the dementia processes in PD can be further studied.
- || CERE-110 / Biogen
Trial completion, Surgery: Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Jul 8, 2019
P2, N=49, Completed, Sponsor: Sangamo Therapeutics
With this protocol, the neural circuits related to the dementia processes in PD can be further studied. Active, not recruiting --> Completed
- CERE-110 / Biogen
Trial primary completion date, Surgery: Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 31, 2016
P2, N=50, Active, not recruiting, Sponsor: Ceregene
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Dec 2019
- CERE-110 / Biogen
Trial completion: CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Oct 30, 2016
P1, N=10, Completed, Sponsor: Ceregene
Trial primary completion date: Dec 2014 --> Dec 2019 Active, not recruiting --> Completed
- | CERE-110 / Biogen
Enrollment closed, Surgery: Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Dec 9, 2012
P2, N=50, Active, not recruiting, Sponsor: Ceregene
Active, not recruiting --> Completed Recruiting --> Active, not recruiting